Omnicell to Acquire MTS Medication Technologies for $156M
Omnicell, Inc., (NASDAQ: OMCL) today announced that it has signed an agreement to acquire MTS Medication Technologies, Inc., a worldwide provider of medication adherence packaging systems, for $156 million, subject to certain adjustments, in a cash transaction. The combination of Omnicell and MTS will create a comprehensive automated medication management offering across the acute and non-acute continuum of patient care.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.